Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 658

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

Open access
Lin, Nancy U., Diéras, Véronique, Paul, Devchand, Lossignol, Dominique, Christodoulou, Christos, Stemmler, Hans-Joachim, Roché, Henri, Liu, Minetta C., Greil, Richard, Ciruelos, Eva, Loibl, Sibylle, Gori, Stefania, Wardley, Andrew, Yardley, Denise, Brufsky, Adam, Blum, Joanne L., Rubin, Stephen D., Dharan, Bernie, Steplewski, Klaudia, Zembryki, Denise, Oliva, Cristina, Roychowdhury, Debasish, Paoletti, Paolo, Winer, Eric P.·2009·Clinical Cancer Research

Abstract

Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical challenge. Lapatinib, an epidermal growth factor receptor/HER2 inhibitor, was associated with regressions of CNS lesions in a small phase 2 trial. The current study was done to further evaluate the CNS activity of lapatinib. The study was later amended to allow patients who progressed on lapatinib the option of receiving lapatinib plus capecitabine. Experimental Design: Eligible patients had HER2+ breast cancer, progressive brain metastases, prior trastuzumab, and cranial radiotherapy. The primary end point was CNS objective response, defined as ≥50% volumetric reduction of CNS lesion(s) in the absence of increasing steroid use, progressive neurologic signs and symptoms, or progressive extra-CNS disease. Results: Two-hundred and forty-two patients entered the study. CNS objective responses to lapatinib were observed in 6% of patients. In an exploratory analysis, 21% of patients experienced a ≥20% volumetric reduction in their CNS lesions. An association was observed between volumetric reduction and improvement in progression-free survival and neurologic signs and symptoms. Of the 50 evaluable patients who entered the lapatinib plus capecitabine extension, 20% experienced a CNS objective response and 40% experienced a ≥20% volumetric reduction in their CNS lesions. Conclusions: This study confirms the modest CNS antitumor activity of lapatinib. Additional responses were observed with the combination of lapatinib and capecitabine. Further studies of lapatinib-based regimens for CNS metastases from HER2+ breast cancer are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-1080

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 658

Metadata

Authors
Lin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., Loibl, S., Gori, S., Wardley, A., Yardley, D., Brufsky, A., Blum, J. L., Rubin, S. D., Dharan, B., Steplewski, K., Zembryki, D., Oliva, C., Roychowdhury, D., Paoletti, P., & Winer, E. P.
Venue
Clinical Cancer Research
Published
2009-02-15
Volume
15
Issue
4
Pages
1452-1459
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2168814163
Cited by
658
References
16
FWCI
47.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-08-1080
The paper
Lin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., Loibl, S., Gori, S., Wardley, A., Yardley, D., Brufsky, A., Blum, J. L., Rubin, S. D., Dharan, B., Steplewski, K., . . . Winer, E. P. (2009). Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-08-1080

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.